Related Experiment Videos
Therapeutic murine monoclonal antibodies developed for individual cancer patients
Abstract:
The purpose of this work was to create antibodies that are highly specific to epitopes on the surface of patient tumor cells that, when added together as a "cocktail," bind to greater than 99% of the patient's tumor cells. We describe the rationale and the methods used to develop new murine hybridomas that secrete monoclonal antibodies reactive with surface markers expressed on breast, lung, colon, kidney, islet cell, and miscellaneous carcinomas and melanoma. A rapid immunofluorescence method (cell concentration fluorescence immunoassay) is also described that has been developed to rapidly screen culture supernatants on viable patient tumor cells, tumor cell lines, or peripheral blood cells. We report the development of one breast, five colon, and three melanoma, three nephroma, and two pancreatic islet cell carcinoma antibodies. The breast antibody binds to 75% of the breast tumors tested thus far and to the same percentage of colon tumors as do the five colon antibodies, 77-85%. The melanoma antibodies described react with 90-100% of the melanoma and prostate cancers tested. The total process of creating the hybridomas and screening the antibodies for potential clinical usefulness has taken from 6 to 9 months to complete, including testing normal tissue reactivity by immunohistochemistry and production of gram quantities of monoclonal antibodies from ascites.
Insights
Researchers developed a novel antibody cocktail targeting multiple cancer types, achieving over 99% binding to patient tumor cells. This breakthrough offers promising potential for improved cancer diagnostics and therapeutics.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Developing highly specific antibodies for cancer detection is crucial.
- Current methods for antibody screening can be time-consuming.
- Targeting surface markers on diverse tumor types presents a significant challenge.
Purpose of the Study:
- To create a cocktail of monoclonal antibodies with high specificity for patient tumor cell surface epitopes.
- To achieve >99% binding to patient tumor cells when antibodies are used in combination.
- To develop a rapid screening method for identifying effective antibodies.
Main Methods:
- Generation of murine hybridomas secreting monoclonal antibodies.
- Screening of antibody reactivity against surface markers on breast, lung, colon, kidney, islet cell carcinomas, and melanoma.
- Development and application of a rapid immunofluorescence method (cell concentration fluorescence immunoassay) for screening.
- Immunohistochemistry for normal tissue reactivity assessment.
- Production of monoclonal antibodies from ascites.
Main Results:
- Successfully developed antibodies for breast, colon, melanoma, nephroma, and pancreatic islet cell carcinomas.
- One breast antibody demonstrated 75% binding to breast tumors and similar reactivity to colon tumors (77-85%).
- Melanoma antibodies showed 90-100% reactivity with melanoma and prostate cancers.
- The entire process from hybridoma creation to screening took 6-9 months.
Conclusions:
- The developed monoclonal antibodies show high specificity and broad reactivity across various carcinomas and melanoma.
- The antibody cocktail strategy holds potential for binding >99% of patient tumor cells.
- The rapid screening assay facilitates efficient development of clinically useful antibodies.
- This work provides a foundation for advanced cancer diagnostics and targeted therapies.